Galectin Therapeutics promotes Khurram Jamil to CMO, replacing Pol Boudes

GALECTIN THERAPEUTICS INC

Dr. Jamil appointed Chief Medical Officer effective August 1, 2024, succeeding Dr. Pol Boudes.
Annual base salary of $500,000, 30% target bonus, 10,000 restricted shares, options for 100,000 shares.
Jamil joined Galectin in March 2024 as VP Clinical Development; previously at Mallinckrodt Pharmaceuticals.
Company reaffirms interim analysis of NAVIGATE Phase 2b/3 trial for belapectin in December 2024.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Pol Boudes

Chief Medical Officer

GALT · GALECTIN THERAPEUTICS INC

Effective: 2024-08-01
Successor: Khurram Jamil
Filed: August 1, 2024, 7:59 PM ET

Dr. Jamil succeeds Dr. Pol Boudes as Chief Medical Officer of the Company, who resigned on July 26, 2024. Dr. Boudes’s last day of employment with the Company is August 1, 2024.

Role change

Khurram Jamil

Chief Medical Officer

GALT · GALECTIN THERAPEUTICS INC

Effective: 2024-08-01
Filed: August 1, 2024, 7:59 PM ET

On August 1, 2024, Galectin Therapeutics Inc. (the “Company”) announced the promotion of Dr. Khurram Jamil to Chief Medical Officer effective immediately.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Pol Boudes resigned as Chief Medical Officer at GALECTIN THERAPEUTICS INC.

Action: resigned
Role: Chief Medical Officer

Exact text from the filing

Dr. Jamil succeeds Dr. Pol Boudes as Chief Medical Officer of the Company, who resigned on July 26, 2024. Dr. Boudes’s last day of employment with the Company is August 1, 2024.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 1.0

Khurram Jamil changed role as Chief Medical Officer at GALECTIN THERAPEUTICS INC.

Action: promoted
Role: Chief Medical Officer

Exact text from the filing

On August 1, 2024, Galectin Therapeutics Inc. (the “Company”) announced the promotion of Dr. Khurram Jamil to Chief Medical Officer effective immediately.

View on SEC.gov

GALECTIN THERAPEUTICS INC filing history →

Source: SEC EDGAR

accession 0001140361-24-035212

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.